Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →
Sai Life Sciences is a contract research, development and manufacturing organization (CRDMO) serving global innovator pharma and biotech companies across the drug lifecycle — discovery chemistry/biology services, process development, and commercial-scale API/intermediate manufacturing from sites in Hyderabad and other locations. It listed on the exchanges in December 2024; revenue is almost entirely from regulated-market innovator clients.
It is among India's leading integrated CRDMO platforms behind the largest players.
Sai Life Sciences Ltd. is a constituent of NIFTY 500, NIFTY SMALLCAP 100, NIFTY SMALLCAP 250, NIFTY SMALLCAP 50. See where it sits on the market heatmap →
Consolidated annual figures taken from Sai Life Sciences Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY26 (year ended 31 Mar 2026).
| Metric | FY26 | FY25 |
|---|---|---|
| EPS (basic, ₹) | 16.63 | 8.83 |
| Book value / share (₹) | 117.28 | 102.12 |
| Return on equity | 14.1% | 8.0% |
| Return on capital employed | 16.6% | 11.0% |
| Operating margin | 21.2% | 15.8% |
| Net margin | 15.9% | 10.0% |
| EBITDA | ₹631 Cr | ₹406 Cr |
| Free cash flow | ₹-84 Cr | ₹-55 Cr |
| Total debt | ₹95 Cr | ₹129 Cr |
| Debt to equity | 0.04 | 0.06 |
| Interest coverage | 11.8 | 3.5 |
| Current ratio | 1.69 | 2.05 |
| Shares outstanding | 21,17,80,000 | 20,84,10,000 |
Open the full income statement, balance sheet and cash flow for SAILIFE →
As disclosed for the quarter ended 30 Jun 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.